Page 374 - Williams Hematology ( PDFDrive )

348 Part V: Therapeutic Principles Chapter 22: Pharmacology and Toxicity of Antineoplastic Drugs 349

134. Ozols RF, Corden BJ, Jacob J, et al: High-dose cisplatin in hypertonic saline. Ann Intern 164. D’Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angio-
MedIntern Med 100:19–24, 1984. genesis. Proc Natl Acad Sci U S A 91:4082–4085, 1994.
135. Peters WP, Henner WD, Grochow LB, et al: Clinical and pharmacologic effects of high 165. Moreira AL, Friedlander DR, Shif B, et al: Thalidomide and a thalidomide analogue
dose single agent busulfan with autologous bone marrow support in the treatment of inhibit endothelial cell proliferation in vitro. J Neurooncol 43:109–114, 1999.
solid tumors. Cancer Res 47:6402–6406, 1987. 166. Muller GW, Chen R, Huang SY, et al: Amino-substituted thalidomide analogs: Potent
136. Phillips GL, Wolff SN, Fay JW, et al: Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9:1625–1630, 1999.
(BCNU) monochemotherapy and autologous marrow transplantation for malignant 167. LeBlanc R, Hideshima T, Catley LP, et al: Immunomodulatory drug costimulates T cells
glioma. J Clin Oncol 4:639–645, 1986. via the B7-CD28 pathway. Blood 103:1787–1790, 2004.
137. Shea TC, Flaherty M, Elias A, et al: A phase I clinical and pharmacokinetic study of 168. Zhu YX, Braggio E, Shi CX, et al: Identification of cereblon binding proteins and rela-
carboplatin and autologous bone marrow support. J Clin Oncol 7:651–661, 1989. tionship with response and survival following pomalidomide and dexamethasone in
138. Dunphy FR, Spitzer G, Buzdar AU, et al: Treatment of estrogen receptor-negative or multiple myeloma. Blood 124:536–545, 2014.
hormonally refractory breast cancer with double high-dose chemotherapy intensifica- 169. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013
tion and bone marrow support. J Clin Oncol 8:1207–1216, 1990. overcomes drug resistance and is well tolerated in patients with relapsed multiple mye-
139. Eder JP, Elias A, Shea TC, et al: A phase I-II study of cyclophosphamide, thiotepa, and loma. Blood 100:3063–3067, 2002.
carboplatin with autologous bone marrow transplantation in solid tumor patients. J 170. Teo SK, Scheffler MR, Kook KA, et al: Thalidomide dose proportionality assessment
Clin Oncol 8:1239–1245, 1990. following single doses to healthy subjects. J Clin Pharmacol 41:662–667, 2001.
140. Jones RJ, Piantadosi S, Mann RB, et al: High-dose cytotoxic therapy and bone marrow 171. Scott LJ: Pomalidomide: A review of its use in patients with recurrent multiple mye-
transplantation for relapsed Hodgkin’s disease. J Clin Oncol 8:527–537, 1990. loma. Drugs 74:549–562, 2014.
141. Kessinger A, Armitage JO, Smith DM, et al: High-dose therapy and autologous peripheral 172. Piscitelli SC, Figg WD, Hahn B, et al: Single-dose pharmacokinetics of thalidomide
blood stem cell transplantation for patients with lymphoma. Blood 74:1260–1265, 1989. in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother
142. Wilson WH, Jain V, Bryant G, et al: Phase I and II study of high-dose ifosfamide, car- 41:2797–2799, 1997.
boplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid 173. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory
tumors. J Clin Oncol 10:1712–1722, 1992. multiple myeloma. N Engl J Med 341:1565–1571, 1999.
143. Umezawa H, Maeda K, Takeuchi T, Okami Y: New antibiotics, bleomycin A and B. J 174. Mileshkin L, Biagi JJ, Mitchell P, et al: Multicenter phase 2 trial of thalidomide in
Antibiot (Tokyo) 19:200–209, 1966. relapsed/refractory multiple myeloma: Adverse prognostic impact of advanced age.
144. Burger RM: Cleavage of nucleic acids by bleomycin. Chem Rev 98:1153–1170, 1998. Blood 102:69–77, 2003.
145. Sebti SM, Jani JP, Mistry JS, et al: Metabolic inactivation: A mechanism of human 175. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus
tumor resistance to bleomycin. Cancer Res 51:227–232, 1991. dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319–4323, 2002.
146. De Haas EC, Zwart N, Meijer C, et al: Variation in bleomycin hydrolase gene is asso- 176. Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT: Incidence and prophylaxis of
ciated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin venous thromboembolic events in multiple myeloma patients receiving immunomod-
Oncol 26:1817–1823, 2008. ulatory therapy. Thromb Res 123:679–686, 2009.
147. Alberts DS, Chen HS, Liu R, et al: Bleomycin pharmacokinetics in man. I. Intravenous 177. Nathan PD, Gore ME, Eisen TG: Unexpected toxicity of combination thalidomide
administration. Cancer Chemother Pharmacol 1:177–181, 1978. and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 20:
148. Karmiol S, Remick DG, Kunkel SL, Phan SH: Regulation of rat pulmonary endothelial 1429–1430, 2002.
cell interleukin-6 production by bleomycin: Effects of cellular fatty acid composition. 178. Ebert BL, Galili N, Tamayo P, et al: An erythroid differentiation signature predicts
Am J Respir Cell Mol Biol 9:628–636, 1993. response to lenalidomide in myelodysplastic syndrome. PLoS Med 5:e35, 2008.
149. Evens AM, Hong F, Gordon LI, et al: The efficacy and tolerability of Adriamycin, ble- 179. Andritsos LA, Johnson AJ, Lozanski G, et al: Higher doses of lenalidomide are associ-
omycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: ated with unacceptable toxicity including life-threatening tumor flare in patients with
A comprehensive analysis from the North American intergroup trial E2496. Br J Hae- chronic lymphocytic leukemia. J Clin Oncol 26:2519–2525, 2008.
matol 161:76–86, 2013. 180. Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed
150. Comis RL: Detecting bleomycin pulmonary toxicity: A continued conundrum. J Clin multiple myeloma in North America. N Engl J Med 357:2133–2142, 2007.
Oncol 8:765–767, 1990. 181. Kizaki M, Nakazato T, Ito K, et al: A novel therapeutic approach for hematological
151. Hutson RG, Kitoh T, Moraga Amador DA, et al: Amino acid control of asparagine syn- malignancies based on cellular differentiation and apoptosis. Int J Hematol 76 (Suppl 1):
thetase: Relation to asparaginase resistance in human leukemia cells. Am J Physiol J 250–252, 2002.
Physiol 272(5 Pt 1):C1691–C1699, 1997. 182. Parkinson D, Smith M: Retinoid therapy for acute promyelocytic leukemia: A coming
152. Kaspers GJ, Veerman AJ, Pieters R, et al: In vitro cellular drug resistance and progno- of age for the differentiation therapy of malignancy. Ann Intern Med 117:338–340, 1992.
sis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90:2723–2729, 183. Sandor V, Bakke S, Robey RW, et al: Phase I trial of the histone deacetylase inhibitor,
1997. depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin
153. Holle LM: Pegaspargase: An alternative? Ann Pharmacother 31:616–624, 1997. Cancer Res 8:718–728, 2002.
154. Ettinger LJ, Ettinger AG, Avramis VI, Gaynon PS: Acute lymphoblastic leukaemia: A 184. Warrell RP Jr, Frankel SR, Miller WH Jr, et al.: Differentiation therapy of acute promyelo-
guide to asparaginase and pegaspargase therapy. BioDrugs 7:30–39, 1997. cytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385–1393, 1991.
155. Semeraro N, Montemurro P, Giordano P, et al: Unbalanced coagulation-fibrinolysis 185. Kakizuka A, Miller WH Jr, Umesono K, et al: Chromosomal translocation t(15;17) in
potential during L-asparaginase therapy in children with acute lymphoblastic leu- human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcrip-
kaemia. Thromb Haemost 64:38–40, 1990. tion factor, PML. Cell 66:663–674, 1991.
156. Bushara KO, Rust RS: Reversible MRI lesions due to pegaspargase treatment of non 186. Collins SJ: Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr Opin
-Hodgkin’s lymphoma. Pediatr Neurol 17:185–187, 1997. Hematol 15:346–351, 2008.
157. Mitchell LG, Andrew M, Hanna K, et al: A prospective cohort study determining the 187. Robertson KA, Emami B, Collins SJ: Retinoic acid-resistant HL-60R cells harbor a
prevalence of thrombotic events in children with acute lymphoblastic leukemia and point mutation in the retinoic acid receptor ligand-binding domain that confers domi-
a central venous line who are treated with L-asparaginase: results of the Prophylactic nant negative activity. Blood 80:1885–1889, 1992.
Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with 188. Muindi JR, Frankel SR, Huselton C, et al: Clinical pharmacology of oral all-trans retin-
Asparaginase (PARKAA) Study. Cancer 97:508–516, 2003. oic acid in patients with acute promyelocytic leukemia. Cancer Res 52:2138–2142, 1992.
158. Heitink-Pollé KM1, Prinsen BH, de Koning TJ, et al: High incidence of symptomatic 189. Muindi J, Frankel SR, Miller WH Jr, et al: Continuous treatment with all-trans retinoic
hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated acid causes a progressive reduction in plasma drug concentrations: Implications for
asparaginase. JIMD Rep 7:103–108, 2013. relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood
159. Nowak-Göttl U, Wermes C, Junker R, et al: Prospective evaluation of the thrombotic 79:299–303, 1992.
risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 geno- 190. Frankel SR, Eardley A, Lauwers G, et al: The “retinoic acid syndrome” in acute promy-
type, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood elocytic leukemia. Ann Intern MedIntern Med 117:292–296, 1992.
93:1595–1599, 1999. 191. De Botton S, Dombret H, Sanz M, et al: Incidence, clinical features, and outcome of
160. Parsons SK, Skapek SX, Neufeld EJ, et al: Asparaginase-associated lipid abnormalities in all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic
children with acute lymphoblastic leukemia. Blood 89:1886–1895, 1997. leukemia. The European APL Group. Blood 92:2712–2718, 1998.
161. Strobeck M: Multiple myeloma therapies. Nat Rev Drug Discov 6:181–182, 2007. 192. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute pro-
162. Roussel M, Lauwers-Cances V, Robillard N, et al: Front-line transplantation pro- myelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341–1348, 1998.
gram with lenalidomide, bortezomib, dexamethasone combination as induction and 193. Miller WH Jr, Schipper HM, Lee JS, et al: Mechanisms of action of arsenic trioxide.
consolidation followed by lenalidomide maintenance in patients with multiple mye- Cancer Res 62:3893–3903, 2002.
loma: A phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol 32: 194. Wang ZY, Chen Z: Acute promyelocytic leukemia: From highly fatal to highly curable.
2712–2717, 2014. Blood 111:2505–2515, 2008.
163. Richardson PG, Siegel DS, Vij R, et al: Pomalidomide alone or in combination with 195. Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al: Arsenic degrades PML or
low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat
phase 2 study. Blood 123:1826–1832, 2014. Cell Biol 10:547–555, 2008.

Kaushansky_chapter 22_p0313-0352.indd 349 9/18/15 10:26 PM